Ozempic for quitting smoking is an emerging research topic as scientists explore whether GLP-1 medications influence smoking and nicotine addiction. Early studies suggest that GLP-1s like semaglutide may reduce nicotine cravings and change smoking behavior for some people.
It is important to know up front that no GLP-1 medication is approved by the U.S. Food and Drug Administration for smoking cessation, and using one for that purpose is off-label.7 Most of the current evidence comes from observational studies and early trials, which can show a link between GLP-1 use and reduced smoking but cannot yet prove that the medication is the cause.2
This article reviews the science behind GLP-1 for tobacco use disorder, including semaglutide, tirzepatide, exenatide, and the investigational drug retatrutide, plus ongoing clinical trials and what to know about smoking or vaping while taking these medications.
Key Facts
- No GLP-1 medication is FDA-approved for smoking cessation. Any use for quitting is off-label and still under investigation.
- Early studies suggest GLP-1s like semaglutide may weaken the brain’s reward response to nicotine and reduce cravings for some people.
- The strongest human data so far is observational, which shows a link but cannot prove the medication causes people to quit.
- One small trial paired exenatide with a nicotine patch and saw higher six-week quit rates than the patch alone.
- There is no formal ban on smoking or vaping while taking a GLP-1, but nicotine works against the same metabolic and heart-health goals.
In This Article:
- The Connection Between Ozempic, GLP-1s and Nicotine
- How Do GLP-1 Medications Curb Nicotine Cravings?
- Examining the Evidence: GLP-1 for Tobacco Use Disorder
- Does Mounjaro Help You Quit Smoking or Vaping?
- Is It Safe to Smoke or Vape While Taking a GLP-1?
- GLP-1 for Smoking FAQs
The Connection Between Ozempic, GLP-1s and Nicotine
Medications such as Ozempic and Wegovy belong to a class of medications called GLP-1 receptor agonists and were originally developed to treat type 2 diabetes and support weight loss.
Recently, researchers and clinicians have begun examining whether Ozempic can help someone quit smoking and whether these medications influence addictive behaviors. Because GLP-1 drugs affect appetite, reward pathways, and impulse control in the brain, scientists are exploring how GLP-1 receptor agonists affect nicotine self-administration and cravings.
Growing interest in GLP-1s for nicotine and tobacco use disorder is driven by both clinical studies and real-world reports.
People using semaglutide frequently describe changes in habits involving alcohol, food and nicotine. Reports of reduced nicotine cravings have prompted researchers to investigate whether these medications might support smoking or vaping cessation. Early observational data support this hypothesis.
While anecdotal, these findings have helped spark formal research into GLP-1 medications; impact on nicotine dependence.
How Do GLP-1 Medications Curb Nicotine Cravings?
Researchers believe GLP-1 medications may influence nicotine dependence because the systems that regulate appetite and addiction share overlapping reward pathways, including dopamine signaling, impulse control and reward reinforcement.
Since nicotine stimulates many of the same neurological circuits that drive food cravings, scientists are exploring whether these medications can also help to reduce compulsive smoking behaviors and help manage nicotine withdrawal.
Blunting the Brain’s Reward System
One of the most promising mechanisms of GLP-1s involves the brain’s dopamine response. Smoking typically triggers strong dopamine surges that reinforce the habit and strengthen the behavioral feedback loop tied to nicotine use.
Semaglutide appears to dampen this dopamine response, weakening the reward signal associated with cigarettes. As the reinforcement loop fades, the psychological pull of nicotine may decline.
Researchers suggest this process may directly reduce semaglutide nicotine cravings, making cigarettes feel less satisfying and easier to resist when you are trying to quit.
23%
23% of nicotine-related comments in a social-media analysis reported quitting nicotine after starting a GLP-1 medication.1
12% to 32%
12% to 32% lower rate of tobacco-use-disorder care among semaglutide users vs. other diabetes medications in a 222,942-person study.2
Mitigating Post-Quit Weight Gain
Fear of weight gain is a major barrier to quitting smoking and a common reason people relapse after cessation.
GLP-1 medications naturally suppress appetite and help regulate blood sugar, which may support healthier eating patterns during nicotine withdrawal. This effect can be particularly helpful during the early stages of quitting, when hunger and cravings often increase.
GLP-1 therapies appear to help control post-cessation weight gain, a factor historically linked to smoking relapse.
Examining the Evidence: GLP-1 for Tobacco Use Disorder
The current evidence is promising but early. Large real-world studies link semaglutide to less tobacco use disorder care, one small trial paired a GLP-1 with a nicotine patch and saw higher short-term quit rates, and several controlled trials are underway. None of this proves a GLP-1 medication causes people to quit, and one longer trial found no lasting difference in quit rates at 12 months.
Here’s a quick summary of the trial status of GLP-1 medications for tobacco use and smoking:
| Medication (brand) | Active ingredient | FDA-approved use(s) | Smoking / nicotine evidence to date | Approved for smoking cessation? |
|---|---|---|---|---|
| Ozempic, Wegovy | Semaglutide | Type 2 diabetes (Ozempic); chronic weight management (Wegovy); cardiovascular risk reduction | Observational EHR data link it to less tobacco use. Controlled trials underway | No (off-label) |
| Mounjaro, Zepbound | Tirzepatide | Type 2 diabetes (Mounjaro); chronic weight management (Zepbound) | Early and anecdotal; no completed smoking-cessation trial. Theory based on shared reward pathways | No (off-label) |
| Byetta, Bydureon | Exenatide | Type 2 diabetes | One small pilot with a nicotine patch showed higher six-week quit rates than the patch alone | No (off-label) |
| Trulicity | Dulaglutide | Type 2 diabetes; cardiovascular risk reduction | RCT showed short-term benefit and less post-quit weight gain, but no lasting difference in quit rates at 12 months | No (off-label) |
| Retatrutide (investigational) | Retatrutide | None; still in clinical trials | No published human studies for smoking; interest is theoretical, based on its GLP-1 activity | No (not approved for any use) |
Interest in GLP-1 for tobacco use disorder has rapidly expanded as researchers move beyond anecdotal patient reports and begin analyzing large clinical datasets.
Early discussions about GLP-1 medications and smoking cessation often came from patients who noticed reduced cravings after starting drugs like semaglutide for diabetes or weight loss.
Today, scientists are examining electronic health records, observational studies and randomized clinical trials to determine whether these medications truly influence nicotine dependence.
This shift toward data-driven analysis is helping researchers understand whether GLP-1 receptor agonists could eventually play a role in treating tobacco addiction.
Large Studies Suggest Semaglutide Reduces Cigarettes Per Day
Large electronic health record studies have provided some of the first population-level insights into how GLP-1s affect nicotine dependence and smoking behavior.
These analyses found that individuals prescribed semaglutide were significantly less likely to seek medical treatment related to tobacco use compared with patients using other medications.
Researchers interpret this pattern as indirect evidence that semaglutide reduces the number of cigarettes per day and decreases nicotine dependence.
If patients are smoking less or experiencing fewer cravings, they may also rely less on additional interventions such as nicotine replacement therapies, prescription cessation medications or repeated clinical visits related to tobacco use disorder.
Ongoing Wegovy Smoking Cessation Trials
Researchers are now testing these observations through controlled clinical trials. Several Wegovy smoking cessation trial phases are currently underway to determine whether GLP-1 medications directly reduce nicotine cravings and smoking behaviors.
Many of these studies are in Phase 2, where researchers evaluate both safety and treatment effectiveness in people attempting to quit smoking. These trials aim to confirm whether GLP-1 therapy causes measurable reductions in tobacco use rather than simply correlating with them.
In fact, dozens of randomized clinical trials are now investigating the safety and efficacy of GLP-1 receptor agonists across multiple substance use disorders, highlighting growing scientific interest in these medications.
The Foundational Exenatide Nicotine Patch Study
Earlier research laid the groundwork. In a pilot randomized controlled trial, 84 smokers with prediabetes or overweight received either exenatide (a GLP-1 receptor agonist) or a placebo, alongside a nicotine patch and brief counseling. After six weeks, more participants in the exenatide group had quit than in the placebo group.4
46% of participants who received exenatide plus a nicotine patch were abstinent at six weeks.4
26% of participants who received a placebo plus a nicotine patch were abstinent at six weeks in the same trial.4
The exenatide group also gained less weight after quitting, which addresses one of the most common reasons people relapse.4 Results like these are encouraging, but the trial was small. A separate randomized trial of a different GLP-1 medication, dulaglutide, found higher quit rates at the end of treatment but no lasting difference at 12 months (32% in both the dulaglutide and placebo groups), a reminder that early benefits do not always hold over time.6
To make the differences between these medications easy to compare, the table below summarizes what each one is approved for and what the smoking evidence looks like so far.
Does Mounjaro Help You Quit Smoking or Vaping?
Interest is growing around whether medications like Mounjaro or Zepbound could support smoking cessation.
These drugs contain tirzepatide, a dual GIP and GLP-1 receptor agonist designed to regulate blood sugar and appetite.
Because GLP-1 medications appear to influence reward pathways involved in addiction, researchers are exploring whether tirzepatide could also help reduce nicotine craving and tobacco use.
Tirzepatide for Vaping Addiction and Smoking
This has sparked discussion about tirzepatide’s dual-hormone mechanism, which may influence dopamine signaling and impulse control in ways similar to semaglutide. Researchers believe these overlapping effects could potentially reduce nicotine cravings, though the human evidence is not yet there.
Online health communities increasingly share tirzepatide quit-smoking success stories, with some users reporting reduced interest in cigarettes or nicotine products.
This has sparked discussions about tirzepatiede’s dual hormone mechanism, which may influence dopamine signaling and impulse control in ways similar to semaglutide.
People also search for retatrutide, an investigational triple-hormone agonist that is still in clinical trials and not approved for any use. Because it acts on GLP-1 pathways, there is theoretical interest in whether it could affect nicotine reward, but no published human studies have tested retatrutide for smoking or vaping.
Anyone considering a GLP-1 medication for nicotine should treat retatrutide as experimental and discuss options with a licensed clinician.
Call A Treatment Provider
For a conversation about what treatment options are available to you.
Make a Call
800-985-8516
Sponsored Helpline
Is It Safe to Smoke or Vape While Taking a GLP-1?
There is no formal rule against smoking or vaping while taking a GLP-1 medication, and nicotine does not chemically “cancel out” the drug. But smoking works against the same metabolic and heart-health goals these medications are prescribed for, and nicotine can worsen insulin resistance and strain the heart. Most clinicians treat continued smoking as a reason to plan a quit attempt, not a safe habit to keep.
Many people start a GLP-1 medication for diabetes or weight management and then wonder whether they can keep smoking or vaping while on it. There is no formal contraindication, meaning no official ban on using nicotine while taking semaglutide or tirzepatide, and no known direct chemical clash between the two.7
The concern is not a dangerous interaction so much as working at cross-purposes. Nicotine increases insulin resistance and raises heart rate and blood pressure, and smoking is a leading cause of cardiovascular disease.8 Since GLP-1 medications are often prescribed to improve blood sugar control and lower cardiovascular risk, continuing to smoke can blunt the very benefits the medication is meant to deliver.
There is also an overlap in side effects. GLP-1 medications commonly cause nausea and other gastrointestinal symptoms, especially early in treatment, and nicotine can add to that discomfort. Vaping raises the same issues as smoking, because most vape liquids still contain nicotine.
Smoking cannabis while taking a GLP-1 is a separate question. Because these medications slow stomach emptying, the timing and intensity of edibles in particular can become unpredictable, and smoking or vaping cannabis still carries its own cardiovascular and respiratory risks. Anyone combining substances with a GLP-1 medication should tell their prescribing clinician so the full picture is accounted for.
The bottom line for safety is straightforward: using nicotine while on a GLP-1 is not known to be acutely dangerous, but it undercuts your health goals, and a clinician can help you turn the medication’s appetite and craving effects into support for a quit attempt.
GLP-1 for Smoking FAQs
Common questions about GLP-1 medications and tobacco use focus on whether these drugs can reduce nicotine cravings or support smoking cessation.
Mounjaro is not approved for smoking cessation. However, some patients report losing interest in cigarettes because tirzepatide may dampen dopamine responses linked to nicotine reward.
Research in animal models and early human studies suggests that with GLP-1 receptor agonists, nicotine self-administration decreases and nicotine triggers a weaker reward response.
Using Ozempic for quitting smoking is off-label. Side effects may include nausea, vomiting and gastrointestinal discomfort, which can sometimes be intensified during nicotine withdrawal.
Never stop taking any medication without first consulting your medical provider. Experts recommend GLP-1 medications as potential adjuncts alongside behavioral counseling and nicotine replacement therapy.
There is no formal ban on smoking while taking a GLP-1 medication, and no known direct chemical interaction. However, nicotine raises insulin resistance and cardiovascular strain, which works against the reasons these drugs are prescribed, and it may add to early nausea. Talk with your prescriber about using the medication as support for quitting rather than continuing to smoke.
Top Addiction Centers Nearby
Finding facilities near you…
References
- Arillotta D, Floresta G, Papanti Pelletier GD, Guirguis A, Corkery JM, Martinotti G, Schifano F. Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach. Brain Sci. 2024;14(6):617. doi:10.3390/brainsci14060617.
- Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes: Target Trial Emulation Using Real-World Data. Ann Intern Med. 2024;177(8):1016-1027. doi:10.7326/M23-2718.
- Tuesta LM, et al. GLP-1 acts on habenular avoidance circuits to control nicotine intake. Nat Neurosci. 2017. (Animal study establishing the GLP-1/nicotine reward mechanism.)
- Yammine L, Green CE, Kosten TR, de Dios C, Suchting R, Lane SD, Verrico CD, Schmitz JM. Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial. Nicotine Tob Res. 2021;23(10):1682-1690. doi:10.1093/ntr/ntab066.
- Effects of Semaglutide on Nicotine Intake. ClinicalTrials.gov identifier NCT05530577. University of North Carolina; and Yammine L, Leidy H, Maki KC, Weaver MF, Bodalski EA, Schmitz JM. A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol. Contemp Clin Trials. 2025;155:107989. doi:10.1016/j.cct.2025.107989.
- Lüthi H, Lengsfeld S, Burkard T, et al. Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial. EClinicalMedicine. 2024;68:102429. doi:10.1016/j.eclinm.2024.102429.
- U.S. Food and Drug Administration. Prescribing information: Ozempic and Wegovy (semaglutide); Mounjaro and Zepbound (tirzepatide). [Editor: link to the current FDA labels for the off-label and side-effect statements.]
- U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: 2014. (Smoking as a cause of insulin resistance and cardiovascular disease.)
